ADC Therapeutics SA ( ADCT ) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. ( TELA ) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. ( ETON ) Reports Q2 Loss, Tops Revenue Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -900.00% and +13.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging ADC Therapeutics ( ADCT ) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - ADC Therapeutics ( NYSE:ADCT )
LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA ADCT, a commercial-stage global leader and pioneer in the field of antibody drug conjugates ( ADCs ) , today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common ...
These 3 Dow Stocks Are Set to Soar in 2025 and Beyond
Plan now for a rotation away from riskier and volatile technology growth stocks and toward blue chips with more promise and predictability.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Pyxis Oncology ( NASDAQ:PYXS )
BOSTON, June 30, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, June 30, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing next-generation antibody-drug conjugate ( 'ADC' ) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of ...
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 ( GLOBE NEWSWIRE ) -- OBI Pharma, Inc. ( OBI ) , a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates ( ADCs ) ( 4174. TWO ) , and TegMine Therapeutics, Inc. ( TegMine ) , a US Biopharma ...
ADC Therapeutics SA ( ADCT ) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 5.26% and 26.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, May 14, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will ...
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - Pyxis Oncology ( NASDAQ:PYXS )
BOSTON, May 14, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. PYXS, a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S.
Zymeworks Inc. ( ZYME ) Reports Q1 Loss, Tops Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, May 08, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, ...
Kura Oncology ( KURA ) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -29.41% and 88.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
AC Immune ( ACIU ) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of 4.55% and 3.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus ( AGEN ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADC Therapeutics SA ( ADCT ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Gene signatures associated with increased efficacy of micvotabart pelidotin ( MICVO ) due to greater linker cleavage were identified based on differential gene expression analysis of ...
LOTTE BIOLOGICS Begins Full-Scale Operation of ADC Manufacturing Facility
Signed a contract to manufacture an ADC therapeutic candidate for an Asia-based company Marks the first order following the completion of LOTTE BIOLOGICS' dedicated ADC manufacturing facility in March, signaling the official launch of its ADC CDMO business
ADC Therapeutics SA ( ADCT ) Reports Q4 Loss, Misses Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 17.14% and 14.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
HUNTSVILLE, March 24, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, ...
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ( "WuXi XDC" or the "Company", stock code: 2268.HK ) , a leading global CRDMO ( Contract Research, Development, and Manufacturing Organization ) specializing in antibody-drug conjugates ( ADCs ) and other ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. ( BEAM ) Reports Q4 Loss, Tops Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 0.91% and 44.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
MAINZ, Germany, February 24, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at ...
BioNTech Completes Acquisition of Biotheus
MAINZ, Germany, February 3, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today the completion of the acquisition of Biotheus ( "Biotheus" ) , a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to ...
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
Avenzo to receive exclusive global license ( excluding Greater China ) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate EGFR and HER3 co-expressed across various solid tumors, including non-small cell lung cancer, breast cancer, ...
Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why - ADC Therapeutics ( NYSE:ADCT )
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why Stephens analyst has initiated coverage on ADC Therapeutics SA ADCT, a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates ( ADCs ) for patients with hematological ...
ADC Therapeutics SA ( ADCT ) Reports Q3 Loss, Lags Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -16.67% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics ( FOLD ) Q3 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25% and 5.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST ( 2:00 p.m. ...
Is ADC Therapeutics ( ADCT ) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
MAINZ, Germany, October 21, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
LONDON, United Kingdom, October 1, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) , alongside its artificial intelligence ( "AI" ) subsidiary InstaDeep Ltd. ( "InstaDeep" ) , today presents an overview of its AI approach during an edition of the Company's ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
• Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older • Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating ...
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
MAINZ, Germany, September 17, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) , alongside its artificial intelligence ( "AI" ) company InstaDeep Ltd. ( "InstaDeep" ) , will host an AI Day, an edition of BioNTech's "Innovation Series", at 09:00 a.m. EDT ( 3:00 p.m.
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
MAINZ, Germany, September 05, 2024 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology ( "ESMO" ) Congress 2024 in Barcelona, Spain from September ...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- ADC Therapeutics SA ( NYSE: ADCT ) , a commercial-stage global leader and pioneer in the field of antibody drug conjugates ( ADCs ) , today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the ...
ADC Therapeutics to Present at Upcoming Investor Conferences
LAUSANNE, Switzerland, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- ADC Therapeutics SA ( NYSE: ADCT ) , a commercial-stage global leader and pioneer in the field of antibody drug conjugates ( ADCs ) , today announced participation in two investor conferences in September: ...
ADC Therapeutics to Present at Upcoming Investor Conferences - ADC Therapeutics ( NYSE:ADCT )
LAUSANNE, Switzerland, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- ADC Therapeutics SA ADCT, a commercial-stage global leader and pioneer in the field of antibody drug conjugates ( ADCs ) , today announced participation in two investor conferences in September: H.C.
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK and MAINZ, GERMANY, August 22, 2024 - Pfizer Inc. ( NYSE: PFE, "Pfizer" ) and BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) today announced that the U.S. Food and Drug Administration ( "FDA" ) has approved the supplemental Biologics License Application for individuals 12 years of age and ...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
NEW YORK and MAINZ, Germany, August 16, 2024 - Pfizer Inc. ( NYSE: PFE, "Pfizer" ) and BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) today announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...
ADC Therapeutics SA ( ADCT ) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ZYNLONTA® net sales of $17.0 million in 2Q 2024. Commercial profitability achieved during first half of ...
Vertex Pharmaceuticals ( VRTX ) Reports Q2 Loss, Misses Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
LAUSANNE, Switzerland, July 30, 2024 ( GLOBE NEWSWIRE ) -- ADC Therapeutics SA ( NYSE: ADCT ) , a commercial-stage global leader and pioneer in the field of antibody drug conjugates ( ADCs ) , today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at ...
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
MAINZ, Germany, July 30, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) today announced positive topline data from the ongoing Phase 2 clinical trial ( EudraCT No.: 2020-002195-12. NCT04526899 ) in patients with unresectable stage III or IV melanoma whose ...
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
MAINZ, Germany, July 22, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.
